[1]
Y. Acikgoz, Y. Ergun, G. Ucar, M. Dirikoc, and D. Uncu, “The Difference in Clinical and Prognostic Features Between De Novo and Recurrent Her2-Positive Metastatic Breast Cancer Patients: Her2-positive metastatic breast cancer patients”, Acta Medica, vol. 50, no. 4, pp. 14–19, Dec. 2019.